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INTRODUCTION
Neuroendocrine tumors are relatively uncommon epithelial
neoplasms with predominant neuroendocrine differentiation. They arise
from most of the organs in the body. Some of the clinicopathological
features of these neuroendocrine neoplasms are characteristic of the site
of origin, while other characteristics are irrespective of their anatomic
site.
Studies on neuroendocrine tumors have concentrated on tumors of
specific organ systems such as gastrointestinal tract, pancreas and Lungs.
Neuroendocrine tumors can arise anywhere in the gastrointestinal tract.
But in the GIT, Neuroendocrine tumors are predominantly derived from
the kulchitsky’s cells or enterochromaffin cells. They present with
different pathologic findings that corresponds to the site of origin and
hormone secreting ability of these tumors.46
Gastrointestinal tract is the most common site to be affected.16 The
incidence of neuroendocrine tumors of GIT is around 67.5% among all
neuroendocrine tumors.53 These tumors develop throughout the
gastrointestinal tract from oesophagus to anus although they are unusual
in the oesophagus and anus.
Small intestine is the most common site of occurrence of
neuroendocrine tumors in the git.30 But most of the recent studies are
against this concept. The pattern of neuroendocrine tumors of git has
changed over the last few years. The prognosis of neuroendocrine tumors
varies according to the grade of the tumor and is distinctly different from
other types of malignancies that occur in GIT. The prognosis of
neuroendocrine tumors is better than adenocarcinomas of the GIT. By
histopathological evaluation and classification they are grouped into
different prognostic categories according to their grade.
Histopathological diagnosis, tumor classification and identification
of histogenesis of metastases of unknown or uncertain primary tumors are
considered to be the most important responsibilities of   practical
histopathologists. At present, in addition to the traditional light
microscopy, there is a list of other informative methods that support
histopathologists in their work such as electron microscopy,
histochemistry, immunohistochemistry and molecular methods.
In the past 20 years, immunohistochemistry has dramatically
developed and has become a very powerful and simple tool in diagnostic
histopathology. Many steps of immune-stain protocols were markedly
simplified and a large number of diagnostic antibodies were introduced to
resolve many diagnostic problems and to increase the diagnostic
accuracy.
As the size of the biopsies decrease, the role of
immunohistochemical stains will become even more important in
determining the origin and differentiation of gastrointestinal tract tumors.
Immunohistochemical stains such as neuron specific enolase,
chromogranin and synaptophysin are commonly used to identify
neuroendocrine tumors.37
In this study we analyse the clinicopathological,
histomorphological and immunohistochemical study of neuroendocrine
tumors of gastrointestinal tract.
AIMS AND OBJECTIVES
1. To evaluate the clinical presentation of neuroendocrine tumors
of gastro intestinal tract.
2. To evaluate their anatomical distribution  in gastro intestinal
tract.
3. To establish the histopathological type of neuroendocrine
tumors of gastro intestinal tract.
4. To carry out immunohistochemical study with neuron specific
enolase, synaptophysin  and chromogranin A.
5. To correlate the  histopathological  type with
immunohistochemical expression
REVIEW OF LITERATURE
The terminology for neuroendocrine tumors varies by anatomic
site. Gastrointestinal neuroendocrine tumors have been variously
described in the literature,   due to their complexity and diversity. They
were first described by T. Langhans and their team in 1867. In 1870,
Heidenhain described neuroendocrine cells in the intestine based on their
chromaffinity. In 1897 Nicholai Kulchitsky identified enterochromaffin
like cells in the crypts of liberkuhn in the intestinal mucosa.
Gastrointestinal neuroendocrine tumors are traditionally known as
carcinoids. The term “karzinoid”- “carcinoma like” was introduced in
1907 by Siegfried Oberndorfer. He found that  some malignant intestinal
tumors  with distinct morphologic characteristics  behaved less
aggressively than adenocarcinomas in the same  site.37 Because of their
slow growth they  were considered to be “cancer-like” than truly
cancerous. Due to the malignant potential of these neoplasms, the term
gastrointestinal neuroendocrine tumors has been used now.
In 1906, Ciaccio described the neuroendocrine origin of carcinoid
tumors and introduced the term enterochromaffin for these cells.46
Huebschmann in 1910 found similarities between tumor cells and
kultschitzky cells in the crypts of Liberkuhn. Argentaffin positivity in
these cells was demonstrated by Andre Gosset and  Pierre Masson in
1914.46 Subsequently endocrine tumors of the gastrointestinal tract and
other sites were named carcinoids.
In 1929, Oberndorfer found the malignant behaviour of carcinoid
tumors and modified his  original description.37 In 1931  Cassidy
described that patients  with these tumors  present with cough, flushing,
cyanosis and diarrhoea and the term ‘carcinoid syndrome’ was
introduced. Rapport isolated and described serotonin in 1948. In 1953 the
secretion of serotonin was confirmed by Lembeck in an ileal carcinoid.
Carcinoid heart disease was identified in 1952 by Gunnar Biorck. Charles
Moertel recognized the relationship between carcinoid tumors and
fibrosis in 1961.37
The histochemical identification of argentaffin and argyrophil cells
by Masson in 1914 and Grimelius  in 1968, helped the pathologists   to
understand the nature of these tumors.58 In 1969, Pearse described
Amine Precursor Uptake and Decarboxylation (APUD) cells, postulating
that they are derived from the neural crest and thus explained the origin
of neuroendocrine cells. These cells have ability to uptake amine
precursor substances and decarboxylate them to produce amines such as
serotonin and catecholamines. In 1987 Lechago, pointed out that not all
endocrine cells [e.g., parathyroid] are capable of APUD, while some
exocrine cell [e.g., paneth cells] are capable.26
One of the major contributions to the study of NETs came from
J.C. Reubi of Bern in 1982 by identifying the cellular location of
somatostatin receptors on neuroendocrine cells and tumors by using both
radiolabelled somatostatin and immunohistochemical antibody
techniques.47
In 1987, Lewin gave the concept of mixed tumors, and the term
was restricted to those tumors in which atleast 30% of the bulk of the
tumor was constituted by neuroendocrine cells. Lewin proposed to
classify mixed tumors histomorphologically into three subtypes:
1. Ampicrine tumors
2. Collision tumors
3. Composite tumors.
In Ampicrine tumors the neuroendocrine and exocrine components
are present within the same cell. In Collision tumor the two elements are
adjacent to each other in a side-by-side pattern. The two elements are
intermingled in a Composite tumor.
In 1989, Somatostatin scintigraphy, the first imaging technique
introduced in the diagnosis of Neuroendocrine tumors. This provides the
therapeutic knowledge in treating somatotstin expressing lesions.
INCIDENCE and PREVALENCE
Neuroendocrine tumors are uncommon malignancies;
bronchopulmonary and gastroenteropancreatic neuroendocrine tumors
together accounts for only 0.5 to 1 percentage of all malignancies.
According to recent studies the incidence of neuroendocrine
tumors is 2.5-5 per one lakh population.41 Oyvind Hauso has found that
the incidence of neuroendocrine tumors is on the rise.15 The current
prevalence is 35 per one lakh population.41
The primary carcinoid tumor of the stomach, lungs, appendix and
caecum is more likely to occur in females. Males are more likely to have
a primary neuroendocrine tumor in thymus, pancreas, duodenum,
jejunum, ileum and rectum.9 But most of the studies found a higher
incidence of Neuroendocrine tumors with in the gastrointestinal system in
men than in women.
SITE
The majority of the neuroendocrine tumors occur in the GIT
(67.5%) and the bronchopulmonary system (25.3%). Within the GIT,
NETs occur in the small intestine (41.8%), rectum (27.4%) and stomach
(8.7%). Less than 1% of the NETs occur in the pancreas.9
RISK FACTORS
Studies from United States found a higher incidence of carcinoid
tumors in African American race when compared to Caucasians. Two
studies found the association between tobacco smoking and small bowel
carcinoid. But it is still in controversy because large studies did not find
any correlation. Family history of MEN I and neurofibromatosis also
have a risk for the development of carcinoids.
CLINICAL FEATURES
Most cases are asymptomatic and found incidentally. Symptoms
can be due to the production of biologically active substances by tumor
cells. In non functioning tumors the symptoms may be due to the local
mass effect or mesenteric fibrois. The common presenting symptoms in
neuroendocrine tumors of GIT are as follows:
Symptoms
 Abdominal pain
 Vomiting
 Diarrohea (irrespective of flushing episodes)
 Intestinal obstruction
 Weight loss
 Bleeding per rectum
CARCINOID SYNDROME
A constellation of symptoms occurs in less than 10% of
neuroendocrine tumors due to excessive levels of hormones like
serotonin, substance P known as carcinoid syndrome.
The features of carcinoid syndrome are as follows:
 Cutaneous Flushing
 Abdominal cramping
 Asthma or wheezing
 Diarrhoea
 Palpitations
 Carcinoid heart disease and congestive cardiac failure
 Peripheral edema
Other manifestations include telangiectasia, pellagra-like skin
lesions.
Carcinoid crisis occurs whenever there is a release of large amount
of hormones in to the blood circulation or hypersecretion from tumors by
trigger factors. Carcinoid crisis presents with, increased heart rate,
profound flushing, unstable blood pressure and bronchospasm.
It can be triggered by factors such as food, alcohol, emotional
events, defecation, embolization therapy, anaesthetic agents, surgery,
radiofrequency ablation or chemotherapy. 9,46
DIAGNOSIS
Neuroendocrine tumors of GIT usually present with obscure
clinical features and require various investigations to establish the final
diagnosis. The diagnosis is based on clinical features, biochemical
analysis, imaging, and confirmation with histopathology.
BIOCHEMICAL ANALYSIS
Blood investigation
Chromogranin A, Serotonin, Gastrin and Histamine.
Urine analysis
24 - Hour urinary excretion of 5-hydroxy indoleacetic acid (5-
HIAA). More than 6 mg / 24 hours - suggestive of carcinoid tumor.
Normal urinary excretion ranges from 2-8 mg / 24 hours.
ULTRASOUND
Ultrasound scans of the abdomen
ENDOSCOPY
Upper esophagogastroduodenoscopy
Colonoscopy
Endoscopic ultrasound
IMAGING
CT, MRI,
PET (18F dopa PET)
SSRS – Somatostatin receptor analogue scan
111In-Labeled somatostatin analogue (octreotide) scan
MIBG -Radiolabeled Meta-iodobenzylguanidine (123I-MIBG)
Gastrointestinal endoscopy and advanced imaging techniques (CT
& MRI) has  now  replaced the old diagnostic methods such as barium x-
ray analysis and electroclysis. These imaging techniques are very much
helpful in the diagnosis of metastatic lesions.
HISTOPATHOLOGY
Biopsy - Histopathology is the gold standard in the diagnosis of
neuroendocrine tumors of GIT.
CLASSIFICATION OF NEUROENDOCRINE TUMORS
Neuroendocrine tumors are classified based on the site of origin,
histomorphology and functional characteristics.
 Functional versus non functional
 Classification based on site of origin
 Histologic classification by WHO
 Classification by tumor stage: TNM
* American joint committee for cancer (AJCC)
* The European neuroendocrine tumor society (ENETS)
 Molecular classification
MEN1 &2, Tuberous sclerosis,Von hippel lindau
disease
FUNCTIONAL VERSUS NON-FUNCTIONAL
Neuroendocrine tumors can be classified as functional and non-
functional based on the hormonal secretion. Functional neuroendocrine
tumors are associated with symptoms that can be attributed to the
secretion of specific peptides or hormones. Nonfunctional neuroendocrine
tumors can also cause non specific symptoms related to increasing mass
(pain, bleeding and obstruction) or metastasis (weight loss). Some
neuroendocrine tumors can remain asymptomatic indefinitely.21
BASED ON SITE OF ORIGIN
Initially classification based on embryogenesis was putforth in
1963 by William and Sandler. They classified these tumors into foregut
carcinoids, midgut carcinoids and hindgut carcinoids.
- Foregut Neuroendocrine tumors
(Stomach, first part of duodenum, lungs)
- Midgut Neuroendocrine tumors
(Appendix, right side of colon, jejunum, second part of
duodenum) 13
- Hindgut Neuroendocrine tumors
(Rectum, sigmoid colon, transverse colon) 23,38
Pancreatic endocrine tumors34
 Gastrinoma
 Glucagonoma
 Insulinoma
 Pancreatic polypeptideoma
 Somatostatinoma
 VIPoma
Additional sites
 Ovary
 Paraganglia
 Adrenal medulla
FAMILIAL SYNDROMES ASSOCIATED WITH NETs 19
 MEN I & II
 Von Hippel Lindau disease
 Tuberous sclerosis
 Neurofibromatosis type I
 Carney complex
Classification based on histology
The classification of carcinoid tumors based on histological
features was introduced by Jun Soga and Kenji Tazawa in 1971. They
divided the carcinoid tumors according to their predominant growth
pattern into insular, trabecular, glandular, mixed and undifferentiated.
Insular pattern seen mostly in “midgut” carcinoids, while the others
“foregut” and “hindgut” show a trabecular pattern.
The first WHO classification of neuroendocrine tumors was
published in the year 1980. In 2000, the term ‘carcinoid’ was removed as
it did not mean the real nature of the tumor which created confusion and
provoked debate between the pathologists and the clinicians. So the term
(neuro) endocrine tumor was introduced.
In 2000 classification, the neuroendocrine tumors were classified
based on the histomorphology. In 2006, grading system was incorporated
into the WHO classification proposed by ENETS which is based on
proliferative rate of tumor cells and the recommended current
classification is WHO 2010.
WHO 1980 CLASSIFICATION
I. CARCINOID
II. MUCOCARCINOID
III. MIXED FORMS CARCINOIDADENOCARCINOMA
IV. PSEUDOTUMOR LESIONS
WHO 2000 CLASSIFICATION
The World Health Organization (WHO) 2000 classification6,41 of
neuroendocrine tumors  is based on behavioural characters, size of the
tumor, depth of invasion and angioinvasion.
1. WELL DIFFERENTIATED ENDOCRINE TUMOR
A) Benign behaviour
B) Uncertain behaviour
2. WELL DIFFERENTIATED ENDOCRINE CARCINOMA
3. POORLY DIFFERENTIATED ENDOCRINE CARCINOMA
4. MIXED EXOCRINE-ENDOCRINE CARCINOMAS
WHO 2000 CLASSIFICATION
Character
Well
differentiate
d  NET
Well
differentiate
d NEC
Poorly
differentiate
d NEC
Biological behavior
Benign/low
malignancy
Low
malignancy
High
malignancy
Metastasis - ± +
Ki-67 index(%) <2 >2 >20
Histological
differentiation
Good Good Poor
Infiltration/angioinvasio
n
Not present Present Present
Tumor size(cm) ≤2 >2 Any size
WHO 2010 classification
* NEUROENDOCRINE TUMOR Grade1(NET G1)
* NEUROENDOCRINE TUMOR Grade2 (NET G2)
* NEUROENDOCRINE CARCINOMA Grade3(NEC)
- LARGE CELL NEC
- SMALL CELL NEC
* MIXED ADENONEUROENDOCRINE CARCINOMA
(MANEC)
Well differentiated NETs can be classified as either grade1 or
grade 2 depending on cell proliferation and histology. Well differentiated
grade1 and grade 2 NETs have traditionally been reported as carcinoids,
regardless of grade or site of origin. According to WHO 2010 guidelines
the term “carcinoid” applies to NET G1 only. Neuroendocrine
carcinomas (NET G3) have a highly aggressive course with rapid
dissemination and resistance to therapeutic interventions.
Comparison of WHO 2000 with WHO 2010 classification
WHO 2000 WHO 2010 HISTOLOGICAL FEATURES
Well
differentiated
endocrine
tumor
NET G1
Well differentiated, mild to moderate
nuclear atypia, corresponds to ENETS
G1 by Ki67 labelling index and mitotic
count
Well
differentiated
endocrine
carcinoma
NET G2
Well differentiated, mild to moderate
nuclear atypia, corresponds to ENETS
G2 by Ki67 labelling index and mitotic
count
Poorly
differentiated
endocrine
carcinoma
NET G3
Poorly differentiated, marked nuclear
pleomorphism, necrosis, corresponds
to ENETS G3 by Ki67 labelling index
and mitotic count
Mixed
Endocrine –
exocrine
carcinoma
Mixed adeno-
neuroendocrine
carcinomas
(MANEC)
Malignant tumors with mixed
glandular and neuroendocrine
characteristics, with atleast 30% of
each component
THE EUROPEAN NEUROENDOCRINE TUMOR SOCIETY
(ENETS) GRADING SYSTEM.
European Neuroendocrine Tumor Society (ENETS) proposed a
histologic grading system based on mitotic rate and Ki-67 labelling index.
The grading system is given below.48,49
Grade Mitotic count (10 HPF) at 40X Ki-67 % labelling index
1 < 2 Upto 2%
2 2-20 3-20%
3 >20 > 20%
* 10hpf (high power fields) is equal to 2 mm2, at least 40 fields at
40x magnification should be evaluated in areas of highest mitotic
density.
* Ki-67 index is the percentage of 2,000 tumor cells in areas of
highest nuclear labelling.
* The grade 2 category identifies and recognises an intermediate
group of NETs  that shows a greater degree of pleomorphism,
mitotic rate and   Ki-67 labelling index than the grade 1 category.
WHO 2010 GRADING SYSTEM CRITERIA
Some of the biological behavior exhibited by neuroendocrine
neoplasms is highly correlated with neoplasm grade. Placing a given
tumor into one of categories depends on well-defined histological
features, size, mitotic counts, Ki-67 labelling index, lymphovascular
invasion, and invasion of adjacent organs, presence of metastases and
whether they produce hormones.
* Grade 1 NETs are  slow growing tumors
* Grade 2 NETs have a less predictable & moderately
aggressive
* Grade 3 Neuroendocrine carcinomas can be highly
aggressive
GRADE CRITERIA
Low grade (G1) Cytologically bland, mitotic count <2 / 10 HPFsand/or ≤ 2% Ki67 index
Intermediate
(G2)
Cytologically bland, mitotic count 2-20 / 10 HPFs
and/or 3%-20% Ki67 index
High(G3) Mitotic count >20 / 10 HPFs and/or  >20% Ki67index
MANEC Tumor has at least 30% of Adenocarcinoma or NEC
NEUROENDOCRINE TUMOR G1 (NET G1)
They can be divided into five histological patterns of growth
* Insular
* Glandular
* Trabecular
* Undifferentiated
* Mixed tumors
Their nuclei are regular; normochromatic with fairly uniform
nuclei, salt-and-pepper chromatin, finely granular cytoplasm, scant
mitoses and necrosis is absent and florid vascularisation.
NEUROENDOCRINE TUMOR G2   (NET G2)
NET G2 includes tumors that are more aggressive both
histologically and clinically than well differentiated neuroendocrine
tumors but are distinguished from poorly differentiated neuroendocrine
carcinomas. It encompasses many tumors that were previously described
by a variety of terms including “atypical” carcinoids, “malignant
tumorlets” etc.60
NEUROENDOCRINE CARCINOMA (NET G3)
NET G3 includes tumors that are poorly differentiated with poor
histological differentiation, mitoses >20 per 10 HPF, angioinvasion.25
MIXED ADENONEUROENDOCRINE CARCINOMA (MANEC)
MANECs have a carcinoma phenotype that is recognizable as both
adenocarcinoma and neuroendocrine carcinoma. Each component should
exceed at least 30% of all neoplastic cells. Both components should be
graded. The identification in adenocarcinomas of scattered
neuroendocrine cells (<30%) does not does not qualify under MANECs.25
TNM  STAGING
TNM staging classification of the neuroendocrine tumors was
initially proposed by European Neuroendocrine tumor society (ENETS)
in 2006. In 2009, the American Joint Committee on Cancer has published
a seventh edition of TNM staging manual that includes gastrointestinal
and pancreatic carcinoids previously no such TNM staging for
neuroendocrine tumors. TNM staging system has some prognostic value
by giving information regarding the extent of local invasion, involvement
of nodes and distant metastasis of the tumors. [See annexure for TNM
staging system for neuroendocrine tumors of GIT]
GROSS:
Neuroendocrine tumors are  small, yellow or tan masses, located in
the submucosa or  intramurally. They can be very firm due to an
accompanying intense desmoplastic reaction. The overlying mucosa may
be either intact or ulcerated.  Some tumors invade deeply to involve the
mesentery.
HISTOPATHOLOGY
NETs are an example of "small blue cell tumors," showing uniform
cells which have round to oval nucleus with stippled chromatin and scant,
pink granular cytoplasm. The cells may be arranged in islands, glands or
sheets. High power examination shows bland histology. There is usually
minimal pleomorphism but less commonly there can be anaplasia, mitotic
activity, and necrosis. Histological pattern of these NETs were well
explained above in the tumor grading.
ELECTRON MICROSCOPY
Electron microscopy reveals the neurosecretory or dense core
granules of the neuroendocrine cells.28
IMMUNOHISTOCHEMICAL MARKERS
In recent years, Immunohistochemical analysis has been widely
used in the diagnosis of neuroendocrine tumors of GIT. The ability to
identify the cells of neuroendocrine differntitaion and the cells of
hormonal secretion by immunohistohistochemical staining is proven
helpful in the study of neuroendocrine tumors of GIT.
The useful neuroendocrine markers are Chromogranin A (CgA),
Synaptophysin (P38), Neuron specific enolase (NSE, gamma-gamma
dimer) and Protein Gene Product (PGP) 9.5. Newer markers introduced in
the diagnosis of neuroendocrine cells are Hsp 70, CDX2 and NSP-55.
CHROMOGRANIN
Chromogranins and secretogranins are the major constituents of
neuroendocrine secretory granules. Chromogranin & secretogranin family
includes chromogranin A, chromogranin B, and Chromogranin C
(Secretogranin II). Chromogranin proteins are distributed in the
Neuroendocrine cells throughtout the body and the functions of these
proteins are unknown. The chromogranin A, was the first to be
discovered in the year 1965. Later it was purified from bovine adrenal
medulla in 1967.50 Chromogranin A is a highly acidic protein with a
molecular weight of 75000. It is an excellent marker for carcinoid
tumors, pheochromocytomas, paragangliomas and other neuroendocrine
tumors. In 1985, chromogranin B with a molecular weight of 100000 was
identified in bovine adrenal medulla and was designated chromogranin B
or secretogranin I.  The predominant component of human chromaffin
granules is chromogranin B.50
At ultra structural level chromogranin is present in dense core
secretory granules the intensity of the immunostain depends on the
number of neurosecretory granules in the cytoplasm of the cells that are
examined. Neuroenocrine cells and tumors with numerous well
developed secretory granules show intense positivity while paucigranular
cells exhibit weak positivity. In paucigranular cels antibodies to other
markers (eg. synaptophysin) may be positive.
Positive Control: Pancreas or adrenal gland
Cellular Localization: Finely granular positivity in cytoplasm
Normal Tissue:  Pancreas
Abnormal tissue: Pheochromocytoma
SYNAPTOPHYSIN
Synaptophysin was first described and named by Wiedenmann.
Synaptophysinn is encoded by the SYP gene. The other name of
synaptophysin is synaptic vesicle protein p38. SYP gene is located on the
short arm of X chromosome (Xp11.23-p11.22). It lies on the Crick
(minus) strand is 12,406 bases in length. The encoded protein has 313
amino acids.  The molecular weight of synaptophysin is 33.845 kDa.
It is a transmembrane calcium-binding glycoprotein present in the
presynaptic vesicles with four transmembrane domains weighing 38kDa.
It is present in neuroendocrine cells and all neurons in the brain and
spinal cord that participate in synaptic transmission. Neuronal cells show
a punctate pattern of staining corresponding to synaptic regions, while
neuroendocrine cells show diffuse cytoplasmic staining pattern. Its
ubiquity at the synapse has led to the use of synaptophysin
immunostaining for quantification of synapses.5
At ultrastructural level synaptophysin is present in microvesicles.
Cells with sparse granules that are chromaffin negative are positive for
synaptophysin. Synaptophysin represents a more specific marker of
neural structure than NSE.20 The exact function of this protein is not
known. It interacts with the synaptic vesicle protein synaptobrevin.
By immunohistochemical staining, it can be demonstrated in a
variety of neural and neuroendocrine tissues, including pancreatic islets
and cells of the adrenal medulla. Synaptophysin can be used to identify
tumors have a origin from neuroendocrine cells such as neuroblastoma,
phaeochromocytoma, carcinoid, and medullary thyroid carcinoma and
others. For diagnostic purposes it is frequently used in combination with
chromogranin A.
Positive Control: Pancreas, colon
Cellular Localization: Cytoplasmic positivity
Normal Tissue: Pancreas, colon
AbnormalTissue: Pheochromocytoma
NEURON SPECIFIC ENOLASE
Neuron specific enolase (NSE) is a glycolytic enzyme which
catalyzes the reaction pathway between 2-phospho-glycerate and
phosphophenol pyruvate. Enolases are homo or heterodimers composed
of three subunits: alpha (α), beta (β) and gamma (γ). Antibodies to the
gamma subunit are most commonly used. The gamma subunits are
primarily expressed in neurons, normal and neoplastic neuroendocrine
cells. But they are also expressed in megakaryocytes, T- lymphocytes,
striated and smooth muscle cells. NSE has a low specificity to
neuroendocrine tumors.  It is commonly used as a screening marker and
the final diagnosis must be supported by other more specific markers.2
Cellular Localization: Cytoplasmic positivity
Normal Tissue: Pancreas, nerve
Positive Control: Pancreas or colon
Abnormal Tissue: Islet cell tumor, medullary and clear cell
carcinomas
Chromogranin, synaptophysin and neuron specific enolase  are the
most commonly used neuroendocrine markers.
CHECKLIST FOR THE REPORTING OF NEUROENDOCRINE
TUMORS OF GIT:
1. Location of the tumor.
2. Multiplicity – if any synchronous multiple tumors found in
the specimen
3. Size
4. Well differentiated or poorly differentiated
5. Extent of local invasion and / or surgical margins
6. Lymphovascular space invasion - Present or absent
7. Perineural invasion - Present or absent
8. Proliferative rate using - mitotic count or Ki-67 labelling
index
9. Lymph node status
10. Distant metastasis - Present or absent
11. Associated diseases e.g. chronic atrophic gastritis,
inflammatory bowel disease, etc.
12. Somatostatin receptor status where applicable.
The summary of the pathology report should have tumor grade
based on WHO 2010 classification (NET G1, NETG2, NEC and
MANEC) and the TNM tumor stage for the specific site.
DIFFERENTIAL DIAGNOSIS
1. HIGH- GRADE LYMPHOMA: Sheets of pleomorphic &
mitotically active blast cells, areas of necrosis. IHC: CD 45, B/T
cell markers.
2. EPITHELIOID GIST: Sheets or nests of cells with eosinophilic
to clear cytoplasm, round to ovoid nuclei, finely dispersed
chromatin and prominent nucleoli. IHC: CD117, CD34.
3. NEUROENDOCRINE CELL HYPERPLASIA: Non-neoplastic
proliferation of neuroendocrine cells. >5 coalescing nodules and
each nodule with >5 endocrine cells in glands/crypts that do not
exceed the diameter of gastric glands.
IMPORTANT POINTS ABOUT NEUROENDOCRINE TUMORS
1. Neuroendocrine tumors can arise most of the organs in the body,
but shares certain basic characters irrespective of the site of origin.
2. Differentiation refers to the extent of resemblance to the normal
cellular counterpart.
3. Grade refers to the degree of biologic aggressiveness which is
more related with differentiation.
4. Stage refers to the extent of spread of the tumor.
5. A number of different systems exist to classify, grade, and stage
the NETs.
6. Although the criteria differ among systems, the underlying basic
data are similar.
7. The proliferative rate in the aspect of mitotic count or Ki-67
labelling index is a critical factor.
8. The local invasion into the organ of origin and involvement of
regional lymph nodes or distant sites are critical factors.
9. Basic information should be included in the pathology reports,
including grade and stage along with reference to the specific
systems being used to define these parameters.21
IMMUNOHISTOCHEMISTRY
Immunological methods in diagnosis were first explained by Coons
and Jones (Coons et al, 1940)7 by using immunofluorescence technique
in bacteria. Immunohistochemistry is based on the selective binding of
specific immunologic reagents to specific antigenic determinants on a
cell.
ANTIGEN
It is any foreign material that can enter the body and trigger a
mechanism of immune response, which results in the production of
antibodies.
ANTIBODY
It is a substance produced in response to an antigenic stimulus.
Immunohistochemistry is used to determine the expression of a
particular antigen and its microanatomic location in a tissue. IHC uses
antibodies by which antigenic differences between the cells can be
identified. The lineage of cell population can be identified based on these
differences and identifies biologically distinct population of cells within
the same lineage.
Immunohistochemistry was first started in 1940 by Coons for
frozen sections. Pierce in 1966, modified it and used for paraffin sections.
Shi in 1991 introduced antigen retrieval technique. In antigen retrieval
technique paraffin processed sections are heated at high temperatures
before IHC staining.  The use of antibody in immunohistochemistry
depends on the sensitivity and specificity of antigen-antibody reaction.
Hybridoma technique provides limitless source of highly specific
antibodies.
Advantages of immunohistochemical methods:
* Can be done on tiny biopsy specimens
* Fresh or frozen tissue is not required
* It can be done on routinely processed tissue sections
* Semi quantification can be done against cells that are
negative for hormone receptor.
* Provides excellent morphological details and tissue
localization.
* Tumor cells expressing hormones can be visualised on the
microscope.
* Expenses are less.
* Provides us with a permanent preparation.
BLOCKING NON-SPECIFIC BACKGROUND STAINING:
Background staining occurs either due to non specific binding or
presence of endogenous enzymes. Non-specific binding with polyclonal
primary antibody can be minimised by pre-incubating sections with
serum from the same species on optimal working dilution.
Endogenous enzymes such as peroxidase seen in normal and
neoplastic tissues are abolished by peroxidase blocking or by using
alternate systems such as immunogold technique. Methods suggested to
overcome endogenous activity include incubation in methanol containing
0.5% hydrogen peroxide for ten minutes at room temperature.
DETECTION SYSTEMS:
Antibodies are labelled or flagged with fluorescent substances,
heavy metals or enzymes to permit visualisation of the antigen. Enzymes
are the most commonly used labels in immunohistochemistry . Incubation
with a chromogen using a standard histochemical method produces a
stable coloured end product suitable for light microscopy.
METHODS:
DIRECT LABELLING METHOD:
Antibody is attached with a label by chemical means and directly
applied to tissue sections. The advantage of this method is that they are
simple to use. The main disadvantage is that the sensitivity is low in this
method.
INDIRECT LABELLING METHOD:
Enzymes are labelled with a secondary antibody, which is
produced against primary antibody. This technique is more sensitive.
AVIDIN BIOTIN CONJUGATE METHOD:
In this technique primary antibody is added followed by
biotinylated secondary antibody and later by preformed complexes of
Avidin and Biotin horse radish peroxidase conjugate. This method is
more specific.
BIOTIN STREPTAVIDIN METHOD:
In this method instead of avidin biotin, Modified  avidin biotin
with streptavidin being used. The advantage of this method is that it
produces less non specific background staining.
IMMUNOGOLD WITH SILVER ENHANCEMENT:
It can be used in both direct and indirect methods. It has found a
wide role in ultrastructural immuno location. The gold particles are
enhanced by addition of several layers of metallic sliver and then used.
This technique may represent the most sensitive and effective light
microscopy immunohistochemical method currently available.
IMMMUNO HISTOCHEMISTRY PROCESS
The tissue for IHC has to undergo fixation, dehydration and
paraffin embedding as in routine H & E sections.
FIXATION
This is a critical step as preservation of morphology is essential for
interpretation of IHC. The ideal fixative is 10% buffered formalin.
According to sample dimensions, 10-24 hours fixation time was
followed. The disadvantage was that antigens were masked during
fixation. It can be overcome by antigen retrieval technique.
According to immunohistochemical staining protocol, biopsies
fixed for less than 6 hours or longer than 72 hours, or sample where
fixation delayed for more than 1 hour do not give proper results.
ANTIGEN RETRIEVAL
This procedure involves unmasking of the antigens. The following
technique can be used.
1. Proteolytic Enzyme digestion
2. Microwave antigen retrieval
3. Pressure cooker antigen retrieval
4. Microwave and trypsin antigen retrieval
Care should be taken not to allow the section to dry after heating,
as this destroys antigenicity. The nuclear details are not clear   in poorly
fixed tissues.  Fatty tissues tend to detach from slides while heating.
CONTROLS
Use of control tissue is essential in immunohistochemistry.   Use of
internal control protects against the effects of poor fixation.
MATERIALS AND METHODS
This study was conducted in our Department of Pathology at
Kilpauk Medical College, Chennai. After approval from ethical
committee of our institution, a total of 53 cases of neuroendocrine tumors
of GIT were included in the study design. All the specimens were
received between September 2008 and September 2012 from the
Department of Surgery and the Department of digestive health diseases,
kilpauk medical college, Chennai.
In each patient the clinical data, including gender, age at the time
of diagnosis, clinical presentation, anatomic site and operative findings (if
present) were obtained from the medical records.
Among the 53 specimens, 45 were biopsies and 8 were resection
specimens. Histopathological study was done in all the specimens as per
standard guidelines. Tumor grading was assigned using the mitotic count
criteria, according to the WHO 2010 classification. Immunohistochemical
analysis was done in 40 cases using antibodies against Neuron specific
enolase, Synaptophysin and Chromogranin.
HISTOPATHOLOGICAL STUDY
All the specimens received were fixed in 10% neutral formalin for
18 - 24 hours. Detailed gross examination of the specimen was done.
Representative samples were taken. The tissues were processed in various
grades of alcohol and xylol using automated histokinette.
The tissue was processed for routine histopathological examination
as follows:
PROCESSING OF HISTOLOGICAL SLIDES
1. Sections of 4-5 μm thickness were cut from processed
paraffin embedded blocks and then gently lowered on the
surface of water bath at 45ºC.
2. The sections were   taken on alcohol cleaned glass slides
smeared with a thin film of egg albumin.
3. The slides with sections were warmed on hot plate at 58ºC
for 1 hour, cooled and stored in a box for staining.
4. Removal of wax was done with xylene. Slides were kept in
xylene for 2 minutes and 2 such changes were done.
5. Xylene was removed with absolute alcohol. The slides were
then kept in absolute alcohol for 2 minutes and two such
changes was made.
6. The sections were treated with descending grades of alcohol
with 90% alcohol for 1 minute and in 70% alcohol for 1
minute.
7. Finally sections were brought into deionised water. The
sections so obtained were processed for H & E staining.
HAEMATOXYLIN AND EOSIN STAINING PROCEDURE
1. Sections are stained in a solution of Harris hematoxylin for
5-15 minutes.
2. Washed thoroughly in running water for 15-30 seconds.
3. Sections were decolorized with 1% acid alcohol solution for
10-20 seconds.
4. Sections are again washed with tap water.
5. Keep in warm water for 5 minutes.
6. Counter stained with 1% aqueous Eosin for 1-15 minutes.
7. Washed rapidly in water to remove excessive amounts of
eosin.
8. Dehydrate by several changes of increasing grades of
alcohol.
9. Cleared in xylene and mounted with Dextrin 80 di-butyl
phthalate xylene(DPX) mountant.
Results
Cytoplasm-Pink
Nucleus-Blue
Immunohistochemistry was done in 40 cases. Suitable blocks were
chosen for IHC. The immunohistochemical stains used were Neuron
specific enolase, Synaptophysin and Chromogranin.
Sections for Immunohistochemistry were also cut in microtome
using disposable blades.  Slides coated with chrome alum were used.
Sections were subjected to antigen retrieval using pressure cooker
technique using citrate retrieval solution (pH 6) and then treated by Horse
Radish Peroxidase (HRP) polymer techniques.
IMMUNOHISTOCHEMICAL STAINS
The following Immunohistochemical antibodies were used from
the Biogenex laboratories.
1. Neuron specific enolase, Mouse monoclonal (MIG-N3).
2. Chromogranin A, Mouse Monoclonal (LK2H10), IgG1,
Kappa
3. Synaptophysin, Mouse Snp 88, IgG3, Kappa.
METHODOLOGY
Coated slides after antigen retrieval were taken through following
stages.
1. Treatment with peroxidise block for inhibiting endogenous
peroxidises in the tissue for 5 minutes.
2. Washed two times in TRIS buffer for 5 minutes.
3. Application of power block for blocking non-specific
antigen- antibody reaction for 5 minutes.
4. Washed two times in TRIS buffer for 5 minutes.
5. Application of primary antibody for 60 minutes.
6. Washed two times in TRIS buffer for 5 minutes.
7. Application of secondary antibody with the tagged Horse
Radish Peroxidase enzyme for 30 minutes.
8. Washed two times in TRIS buffer for 5 minutes.
9. Application of super enhancer for 30 minutes which
enhances the final reaction product by increasing the
sensitivity of antigen - antibody reaction.
10. Washed two times in TRIS buffer for 5 minutes.
11. Application of DAB (Diamino benzidine)  chromogen for  5
minutes - this is cleaved  by  enzyme  to give the coloured
product.
12. Washed in distilled water for 5 minutes.
13. Counterstaining of slides done with hematoxylin.
14. Air dried and mounted with DPX.
RESULTS
Neuron specific enolase:
Positive: Cytoplasmic-brown
Nucleus –blue.
Synaptophysin:
Positive:  cytoplasmic , membranous or granular-brown
Nucleus: blue
Chromogranin:
Positive: Granular cytoplasmic – brown
Nucleus: blue
OBSERVATION AND RESULTS
TABLE - 1
INCIDENCE OF NEUROENDOCRINE TUMORS
Duration of
study ( 4 years)
Total no of
specimens
Total no of
malignancies
Total  GIT
malignancies
NET
of
GIT
September 2008
To
September2012
20828 1423 886 53
The Total number of specimens received during the period of 2008
(September) to 2012 (September) were 20828. Out of the 20828
specimens, 886 specimens were GIT malignancies. Among the 886
specimens 53 specimens were diagnosed as neuroendocrine tumors of the
GIT.
In our study the incidence of neuroendocrine tumors of GIT over
the period of four years was 5.98 %. The incidence of neuroendocrine
tumors of the GIT among the total malignancies was 3.72%.
TABLE - 2
AGE DISTRIBUTION OF NEUROENDOCRINE TUMORS OF
GIT
AGE GROUP
(years)
CASES
NUMBER PERCENTAGE (%)
21-30 3 5.7
31-40 11 20.8
41-50 14 26.4
51-60 15 28.3
61-70 9 17.0
71-80 1 1.9
TOTAL 53
This table shows the incidence of neuroendocrine tumors of GIT in
different age groups. In our study the youngest person affected was 25
years and the eldest one was 71 years old. The maximum number of cases
[15/53, (28.3%)] reported was between 51and 60 years of age. About
74% of the cases were more than 40 years with the median age of 50
years.
TABLE - 3
GENDER DISTRIBUTION OF NEUROENDOCRINE TUMORS
OF GIT
GENDER NO OF CASES PERCENTAGE (%)
Male 32 60.37
Female 21 39.62
TOTAL 53
In our study, the occurrence of NET of GIT was more common in
males when compared to females. Among 53 specimens, 32 specimens
belonged to male patients and 21 specimens were from female patients.
In our study, the incidence of NET of GIT was higher in males
with 60.37%. The observed male: female ratio is 1.5:1.
TABLE - 4
COMPARISION OF CLINICL FEATURES
SYMPTOMS NO OF CASES PERCENTAGE (%)
Loss of weight and appetite 21 39.6
Vomiting 9 16.9
Abdominal pain 28 52.8
Diarrhoea 2 3.7
Obstructive jaundice 5 9.4
Bleeding Per Rectum 4 7.5
In our study the most common presenting clinical feature was
abdominal pain. 28 (52.8%) patients presented with abdominal pain
followed by loss of weight and appetite in 21 (39.6%) patients. Diarrhoea
was a rare presentation seen only in 2 (3.7%) patients.
TABLE – 5
CARCINOID SYNDROME
TOTAL NO OF
CASES
CARCINOID
SYNDROME
PERCENTAGE
(%)
53 02 3.8
Out of the 53 cases Carcinoid syndrome features were present only
in 2 cases. In our study the incidence of Carcinoid syndrome is 3.8%.
TABLE - 6
COMPARISON OF TYPE OF SPECIMEN RECEIVED
SPECIMEN NO OF SPECIMEN PERCENTAGE (%)
Biopsy 45 85
Resection 8 15
TOTAL 53
Among 53 samples of NET of GIT, 45 were biopsy specimens and
8 were resection specimens. In our study biopsy specimens constitute
large proportion with 85% when compared to resection specimens which
is only 15%.
TABLE - 7
SITE DISTRIBUTION OF NET OF GIT
SITE NO OF CASES PERCENTAGE (%)
Oesophagus 1 1.9
Stomach 24 45.3
Small Intestine 18 33.9
Appendix 1 1.9
Colon 5 9.4
Rectum 4 7.5
TOTAL 53
Among 53 cases, 24 specimens from stomach, 18 from small
intestine and the specimens from other sites colon, rectum, appendix, &
oesophagus were 5, 4, 1&1 respectively.  In our study the most common
site involved was stomach constituting 45.3% followed by small intestine
33.9%. The least common were appendix and oesophagus with one case
each. Colon and Rectum were intermediate with 9.4% and 7.5%
respectively.
TABLE - 8
HISTOLOGICAL GRADING
DIAGNOSIS NO OF CASES PERCENTAGE(%)
Neuroendocrine tumor grade1
(NET G1)
22 41.5
Neuroendocrine tumor grade2
(NET G2)
9 17
Neuroendocrine carcinoma
(NEC)
4 7.5
Mixed adenoneuroendocrine
carcinoma (MANEC)
18 34
TOTAL 53
Histological grading was done according to WHO 2010
classification to compare the histopathological pattern of NET of GIT. In
our study the Neuroendocrine tumor Grade 1(NET G1) was found in 22
cases followed by Neuroendocrine tumor G2 (NET G2) in 9 cases and
Neuroendocrine carcinomas (NEC) in 4 cases. Mixed
Adenoneuroendocrine carcinoma (MANEC) found in 18 (34%) cases
irrespective of the tumor grade, can be either well differentiated (NET
G1/ G2) or poorly differentiated (NEC) and these cases were not included
in any of the tumor grade (G1to NEC) and dealt separately in this study.
In our study the most frequent histological grade was
neuroendocrine tumor G1 with 41.5% and the least one was
neuroendocrine carcinoma with 7.5%.
TABLE - 9
SITE WISE DISTRIBUTION OF NEUROENDOCRINE TUMORS
SITE NET GI NET G2 NEC MANEC TOTAL
OESOPHAGUS
1
(100%)
0
(0)%
0
(0)%
0
(0)%
1
STOMACH
8
(33.3%)
6
(25%)
1
(4.2%)
9
(37.5%)
24
SMALL
INTESTINE
10
(55.6%)
2
(11.1%)
1
(5.6%)
5
(27.8%)
18
APPENDIX
1
(100%)
0
(0)%
0
(0)%
0
(0)%
1
COLON
0
(0)%
0
(0)%
2
(40%)
3
(60%)
5
RECTUM
2
(50%)
1
(25%)
0
(0)%
1
(25%)
4
TOTAL 22 9 4 18 53
The above table shows the anatomical site distribution of
neuroendocrine tumors according to WHO 2010 grading. Large
proportion of cases reported from stomach & small intestine and least
number of cases from appendix and oesophagus. In the stomach major
histological differentiation was MNAEC with 37.5%, followed by NET
G1with 33.3%, and NET G2 accounted for 25%. But in small intestine
majority of cases were NET G1 with 55.6% followed by MANEC with
27.8%, and NET G2 accounted for 11.1%.
Among the five cases in colon, 2 were NEC and 3 were MANEC.
Among that occurred in Rectum 2 were NET G1, 1 was NET G2, and 1
was MANEC. Histological differentiation found in appendix and stomach
was NET G1.
TABLE - 10
METASTASIS
TOTAL NO OF
CASES
LIVER
METASTASIS
PERCENTAGE
(%)
53 03 5.7%
Metastasis was seen in 3 cases. In all the cases the site of
metastasis was the liver. The incidence of metastasis to liver was 5.7%.
TABLE-11
AGE GENDER PRIMARY SITE GRADE
48 M COLON MANEC
50 M RECTUM MANEC
0 F STOMACH NET G2
The primary sites for the liver secondaries were colon, rectum and
stomach. The histological diagnosis of the primary sites was found to be
MANEC in colon & rectum and NET G2 in stomach. Among 3 cases, 2
patients were male and all of them were in the 4th decade of age.
TABLE - 12
IMMUNOHISTOCHEMICAL EXPRESSION OF NET OF GIT
MARKERS
POSITIVE
CASES
PERCENTAGE
NEURON SPECIFIC
ENOLASE
38 95
SYNAPTOPHYSIN 35 87.5
CHROMOGRANIN 33 82.5
TOTAL NO OF CASES 40
Immunohistochemical staining was studied in 40 cases out of 53.
In which, neuron specific enolase was positive in 38 cases, synaptophysin
was positive in 35cases and chromogranin was positive in 33 cases. When
we compared the expression of immunohistochemical marker, higher
incidence was found in neuron specific enolase with positive percentage
of 95% followed by synaptophysin (87.5%) and chromogranin (82.5%).
TABLE - 13
EXPRESSION OF NSE WITH RELATION TO TUMOR GRADE
GRADE POSITIVE NEGATIVE TOTAL
NET G1 19 0 19
NET G2 7 0 7
NEC 3 1 4
MANEC 9 1 10
TOTAL 38 2 40
[Chi-square value= 5.263 (df-3)
p value=0.154. The distribution is not significant (p >0.05)]
Both NET G1 and NET G2 expressed positivity for Neuron
specific enolase in all cases. In NEC 3cases were positive and one was
negative. In MANEC 9 cases were positive with one negative. In this
study the correlation between the tumor grade and the expression of
Neuron specific enolase was not statistically significant (p>0.05). Neuron
specific enolase positivity was seen in most of the cases (38/40)
irrespective of the tumor grade.
TABLE - 14
EXPRESSION OF SYNAPTOPHYSIN WITH RELATION TO
TUMOR GRADE
GRADE POSITIVE NEGATIVE TOTAL
NET G1 19 0 19
NET G2 6 1 7
NEC 2 2 4
MANEC 8 2 10
TOTAL 35 5 0
[Chi-square value = 8.392 (df-3)
p value = 0.039.*      The distribution is significant (p<0.05)]
Out of the 40 cases positivity for synaptophysin was seen in all
cases of NET G1. In NET G2, 6 cases were shown positive results and
one was negative. In NEC, 2cases were positive and 2 were negative. In
MANEC, 8 cases were positive with 2 negative results. The association
between tumor grade and the expression of synaptophysin was
statistically significant (p<0.05) at 95% confidence interval.
In our study we found that expression of synaptophysin has
significant correlation with tumor grade in most of the cases of NET of
GIT.
TABLE - 15
EXPRESSION OF CHROMOGRANIN WITH RELATION TO
TUMOR GRADE
GRADE POSITIVE NEGATIVE TOTAL
NET G1 18 1 19
NET G2 6 1 7
NEC 2 2 4
MANEC 7 3 10
TOTAL 33 7 0
[Chi-square value = 6.029 (df-3)
p value = 0.110.  The distribution is not significant (p>0.05)]
Chromogranin expressed positivity for 18 cases in NET G1, 6
cases in NET G2, 2 cases in NEC and 7 cases in MANEC from the total
of 19, 7, 4, and 10 cases respectively. The expression of Chromogranin
was statistically not significant (p>0.05).
The negative expression pattern of chromogranin was more when
compared to other markers [7 cases with CgA, but only 5cases & 2 cases
gave negativity with SYN and NSE respectively]. In our study the tumors
expressing chromogranin was less. So it becomes a less sensitive marker
in the diagnosis of NET of GIT even though it has some specificity.
DISCUSSION
Gastrointestinal Neuroendocrine tumors are rare malignant tumors.
Due to improved diagnostic and therapeutic modalities, they have gained
attention over the last few years. From all over the world, there is limited
epidemiological data available for neuroendocrine tumors of GIT. In
India, studies conducted on neuroendocrine tumors of GIT are less.
Hence, this study was planned to determine the pattern of NET of GIT in
our population.
After approval from our ethical committee, this descriptive study
was conducted in our department of pathology at Kilpauk medical college
& hospital. In this study, a total of 53 specimens received between
September 2008 and September 2012 diagnosed as having
neuroendocrine tumors of GIT were analysed for histopathological and
immunohistochemical expression.
At present, it is estimated that the incidence of GEP-NETs is
approximately 2.5 to 5.0 cases per 100,000 in the United States which
indicates the low incidence of these tumors.41 But the SEER database
suggests that their prevalence has increased dramatically over the last
three decades. In fact, it is believed that the incidence of these tumors is
increasing globally. It is likely that this increase is due to an increase in
the actual number of cases and/or increased clinical and pathological
experience with diagnosing this disease.15
In our study the incidence of Neuroendocrine tumors of the GIT
constitute about 3.72% of total malignancies. Among the GIT
malignancies they constitute about 5.98 % which is higher when
compared to the studies conducted by Maroun et al31 (constitute <2% of
all GIT malignancies) and Niederle et al40 (constitute 1.49% of the
malignancies of digestive tract).
AGE
The median age at diagnosis of NET of GIT in the present study
was 50 years with the age range between 25 years and 71 years. Most of
the studies correlated with our study having average age at initial
diagnosis between 50 and 60 years.
Amarapurkar et al1 have done a retrospective analysis of NET of
GIT and Pancreas in 74 patients. In their study the mean age at diagnosis
was 53.01±15.13 years. Estrozi and Bacchi9 found an average of 52.8
years in 773 cases of Gastroenteropancreatic Neuroendocrine tumors.
Rothenstein et al51 also showed the mean age of 56 years in their study of
193 patients with NET of the gastrointestinal tract which demonstrated
that 72% were NET/carcinoids. Neuroendocrine tumors were rare in
paediatric age group.
SEX DISTRIBUTION
In our study males had higher incidence of NET of GIT with
60.37%. The observed male: female ratio is 1.5:1. Most of the studies
correlated well with our study. The same male preponderance was
observed by Yao et al.2008 (M: F=1.2:1) in USA and by Ito et al.2010
(M: F 2:1) in Japan and also by Niederle et al. 2010 (M: F=1.08:1) in
Austria.40 Rothenstein et al & Amarapurkar et al also showed that males
were commonly affected with M: F ratio of 2:1. In contrast, Estrozi and
Bacchi found higher number of neuroendocrine tumors in females.
SITE DISTRIBUTION OF NET OF GIT
Overall, the GIT represents the site of greatest NET incidence
(64.3%), followed by the bronchopulmonary system (27.9%). In our
study the most common site involved is Stomach constituting 5.3%
followed by small intestine 33.9% and large intestine (Colon - 9.4%,
Rectum - 7.5%). This is in contrast to previous studies (Modlin et al.
2003, Maggard et al. 2004, Helland et al. 2006, Borislav et al 2007 and
Lombard - Bohas et al. 2009)40 stating the small intestine as the most
frequent site. Over a decade the controversy is existing between the small
intestine and the stomach as the common site of occurrence of NET.
Initially, Kloppel et al. 2007 suspected stomach as the preferential site of
NET of GIT. Now most of the studies revealed that the stomach as the
commonest site of NET of GIT. Following Kloppel et al, Niederle et al
(2010) also reported that stomach was the commonest site (22.8%)
followed by appendix (21%). A study conducted by Amarapurkar et al
(2010) in India with stomach (30.2%) being the common site followed by
pancreas (23.3%). Estrozi and Bachi (2011) also found that stomach
(24.5%) was the most common anatomic location followed by small
intestine (20.5%).
Hodgson et al17 in 2005 have shown statistically significant increae
of about eight to nine fold increase in the incidence of gastric
neuroendocrine tumors. Modlin et al37 have shown significant increase in
incidence of gastric neuroendocrine tumors from 2.4 to 8.7 %. A study
from India by Hegde et al16 has also shown rising incidence of gastric
NETs as compared to the past.
An explanation for the increase may be the greater use of
endoscopic diagnostic procedures and biopsies as a routine for all cases,
even with small gastric lesions. The widespread use of proton pump
inhibitors and increase in endoscopic biopsies has been found to be the
reasons for the increased incidence of neuroendocrine tumors of GIT.
The most common symptom presented in our study was abdominal
pain and other symptoms were vomiting, loss of weight and appetite,
diarrhoea, bleeding per rectum etc.
According to Niederle & Niederle (2011),40 the most common
symptom was abdominal pain. About 29.5% (71 of 241) of cases
presented with abdominal pain in their study which correlates with our
study.
Carcinoid syndrome is frequently discussed in relation to carcinoid
tumors. Carcinoid syndrome found in 3 (4.1%) patients out of the 74
patients in a study conducted by Amarapurkar et al is very much
comparable with our study were carcinoid syndrome found in 2 patients
(3.8%). However, the complex of flushing, diarrhoea, abdominal pain,
and occasional asthma or right-sided valvular problems is actually
uncommon. Ito et al and Soga et al study also show that less than 10%
(1.7%-8.4%) of neuroendocrine tumors exhibit some of these
symptoms18,54. The conducted by Warrell et al. (2003)59 Carcinoid
syndrome occured in 10 % of the cases.
HISTOPATHOLOGICAL GRADING
In our study histological grading was done according to WHO
2010 classification published recently. The most frequent histological
grade was found to be Neuroendocrine tumor G1 (NET G1) with 41.5%
and the last one was Neuroendocrine carcinoma (NEC) with 7.5%.
Most of the studies show that the majority of neuroendocrine
tumors of GIT belong to G1, which correlated with our study. Estrozi and
Bacchi (2011) used WHO 2010 classification and the ENETS scheme in
their study and found G1 (NETG1, with a mitotic count of <2 per 10 high
power fields (HPF) and a Ki-67 index ≤2%) tumors are the commonest
with 73.2%.  Niederle & Niederle (2011) reclassified 77 cases of
gastroenteropancreatic neuroendocrine tumors according to WHO 2010
classification and they also concluded that the majority of neuroendocrine
tumors of GIT were G1 (59.7%) and G2 (31.2%) independent of their
staging. In their study the NET G3 (NEC-Neuroendocrine carcinoma) are
very rare and found in stomach, colon and rectum with 9.1% which is
near comparable to our study with 7.5 % of NEC diagnosed in stomach,
colon and small intestine. Borislav et al (2007) showed that out of the 38
cases, 29 were G1, 7 were G2, and 2 were G3 based on WHO 2000
classification which is nearly equal to NET G1, NET G2, and NEC of
WHO 2010 classification.
The presence of a neuroendocrine component in gastrointestinal
adenocarcinoma is often reported. Similarly, the presence of an exocrine
component in NET of GIT, especially in high grade neuroendocrine
carcinomas, has also been widely documented. There is a wide spectrum
of such combinations of exocrine and neuroendocrine components
ranging from adenomas or carcinomas with interspersed neuroendocrine
cells at one end to classical neuroendocrine tumors with a focal exocrine
component on the other end. In the 2000 WHO classification such
neoplasms were defined as mixed exocrine-endocrine tumors when each
component represents at least 30% of the lesion. In the most recent WHO
2010 classification of neoplasms of the gastrointestinal tract, such
neoplasms are called “mixed adenoneuroendocrine carcinomas”
(MANECs). Mixed Adenoneuroendocrine Carcinomas (MANECs) have
a carcinoma phenotype that is recognizable as both adenocarcinoma and
neuroendocrine carcinoma with each component exceeding at least 30%
of all neoplastic cells & both components should be graded. The
identification in adenocarcinomas of scattered neuroendocrine cells
(<30%) does not qualify for MANEC.
In our study 34% (18/53) of cases showed Mixed
Adenoneuroendocrine carcinoma (MANEC) which is irrespective of the
tumor grade. These cases were not included in the any of the tumor grade
even though they can be classified as well differentiated (NET G1/ G2) or
poorly differentiated (NEC) at present study. Previous studies regarding
MANEC were mostly case reports or just documentation. An update on
MANEC by La Rosa et al (2012)25 informs that approximately 100
documented cases have appeared in the literature. Most of these
neoplasms have been reported in the oesophagus, stomach, ampullary
region, large bowel and anorectal region. Most of the MANEC with NET
component were commonly found in stomach with male preponderance,
around the age of 53 years and with liver metastasis in a few cases, which
correlates with our study. In our study MANEC was found mostly in
stomach with higher incidence rate (37.5%) followed by the small
intestine (27.8%). Most of the studies discussed above have not studied
the MANEC or mixed exocrine-endocrine tumors. Now it is important to
classify them because gastric MANEC shows a better prognosis than
gastric NEC. The diagnosis of MANEC mostly incomplete because
frequently only one component of the neoplasm is identified. Now it is
important to classify them because gastric MANEC shows a better
prognosis than gastric NEC.24 So the discussions regarding MANEC
require further studies based on WHO 2010 classification of NETs of
GIT.
IMMUNOHISTOCHEMISTRY
Various studies have published on immunohistochemical
expression of NET of GIT from 1996 (Blumenfeld W et al)4 to till date.
Most of the studies confirmed that Neuron Specific Enolase (NSE),
Synaptophysin and Chromogranin were useful markers in the diagnosis
of NET of GIT.
When we analyse the recent studies, the positivity rate for NSE,
SYN and CgA was 100%, 100% and 61.9% by Fen-Yau Li et al10 (2010);
85.7%, 100% and 42.9% by Uchiyama et al56 (2012); which is
comparable with our results of 95%, 87.5% and 82.5% respectively. In
our study we found that expression of Synaptophysin has significant
correlation with tumor grade in most of the cases of NET of GIT. Even
though Synaptophysin has significant correlation, we cannot use a single
marker to confirm the diagnosis of neuroendocrine tumors.  Due to the
difference in the positive percentage, no single marker can be relied on
exclusively and the use of adequate panel of markers is always advisable
to confirm or exclude the final diagnosis.
The immunoreactivity with negative expression pattern was more
with Chromogranin when compared to other markers [7 cases with CgA,
but only 5 cases & 2 cases gave negativity with SYN and NSE
respectively] in our study. And the number of cases showing negative
expression was more with NEC and MANEC when compared to NET G1
& NET G2. According to Rindi et al49 the Well Differentiated NETs tend
to exhibit diffuse and intense expression of CgA and synaptophysin,
whereas Poorly Differentiated neuroendocrine carcinomas show
significantly reduced CgA expression while maintaining intense staining
for synaptophysin. Chromogranin positivity generally correlates with the
extent of granularity on electron microscopy. The intensity of the
immunostain depends on the number of neurosecretory granules in the
cytoplasm of the cells examined as in small cell carcinoma, which
synthesizes actively chromogranin, but because of paucity of cytoplasm
and scarcity of neurosecretory granules, shows usually very weak
chromogranin stain. Chromogranin A may be negative in Somatostatin
positive duodenal NET and Rectal NET.
Neuron-specific enolase is a cytoplasmic enzyme detected in
tumors of neuroendocrine differentiation, but lacks specificity compared
to CgA and synaptophysin. NSE usually used as a screening marker and
the diagnosis must be supported by other more specific markers.
Immunohistochemical expression by neuroendocrine portion of the mixed
adenoneuroendocrine carcinoma will be most useful in diagnosing the
MANEC.
Immunohistochemical study with neuroendocrine markers may be
very useful to confirm the nature of the tumor based on endoscopic tiny
biopsy specimens in many cases where histological diagnosis becomes
difficult. In distant metastasis, immunohistochemical study gives accurate
definite diagnosis of origin and differentiation of primary neuroendocrine
tumors. Thus immunohistochemistry has a definite role in the diagnosis
of neuroendocrine tumors of GIT.
SUMMARY AND CONCLUSION
Neuroendocrine tumors of the GIT, known to be  rare tumors,
presents with increased incidence over the recent decades, most probably
due to the increased awareness among the physicians and improved
diagnostic techniques.
In this study we analysed the clinicopathological and
immunohistochemical characteristics of 53 neuroendocrine tumors and
the findings are summarized below.
1. Neuroendocrine tumors of the GIT constituted 3.72% of all
malignancies.  Among the  GIT  malignancies  they  constitute
about 5.98 % of the malignancies.
2. The common age group affected was 51-60 years with the median
age of 50 years.
3. Males were commonly affected, with male: female ratio of 1.5:1.
4. Stomach being the common site with 45.3% followed by small
intestine with 33.9%.
5. Most common tumors diagnosed were neuroendocrine tumor G1
(41.5%) followed by NET G2 (17%). Mixed adenoneuroendocrine
carcinomas   presented with equal incidence with NET G1.
6. The positivity rate for neuron specific enolase, synaptophysin, and
chromogranin was 97.5%, 87.5%, and 82.5% respectively.
Synaptophysin had significant correlation with tumor grade. Even
then a panel of markers should be used to prevent the error in
diagnosis.
To conclude, neuroendocrine tumors of GIT are distinct neoplasms
that differ clinically, histomorphologically and immunohistochemically
from other tumors of GIT. So confirmation of histopathological diagnosis
by immunohistochemistry is important to give a definitive diagnosis as
the prognosis and treatment of these tumors differs from other tumors.
Immunohistochemistry should be done with a panel of markers to avoid
the error in diagnosis.
BIBLIOGRAPHY
1. Amarapurkar DN, Juneja MP, Patel ND. "A retrospective clinico-
pathological analysis of neuroendocrine tumors of the gastrointestinal
tract". Trop Gastroenterology 2010;31(2): 101–104.
2. Bajetta E, Ferrari L, Martinetti A, et al. "Chromogranin A, neuronspecific
enolase, carcinoembryonic antigen, and hydroxyindole acetic acid
evaluation in patients with neuroendocrine tumors". Cancer 1999;86(5):
858-865.
3. Berretta, M. "Biomarkers in neuroendocrine tumors". Frontiers in
Bioscience 2010;S2: 332-342.
4. Blumenfeld W, Chandhoke DK, Sagerman P, et al. "Neuroendocrine
differentiation in gastric adenocarcinomas. An immunohistochemical
study." Arch Pathol Lab Med 1996;120(5):478-481.
5. Calhoun ME,   Jucker M,  Martin LJ,  et  al. "Comparative   evaluation  of
synaptophysin – based   methods   for   quantification   of   synapses".  J
Neurocytol 1996;25 (12): 821–828.
6. Cappella C, Heitz PU, Hoffler H, et al. "Revised classification of
neuroendocrine tumors of  the lung, pancreas and gut". Virchows Arch
1995;425: 547-560.
7. Coons AH, Creech HJ, Jones RN. "Immunological properties of an
antibody containing a fluorescent group". Proc Soc Exp Biol Med 1941; 47:
200-202.
8. Creutzfeldt W. "Carcinoid tumors: Development of our knowledge". World
J Surg 1996;20: 126-131.
9. Estrozi B, Bacchi CE. "Neuroendocrine tumors involving the
gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases".
CLINICS 2011;66(10): 1671-1675
10.Fen-Yau Li A, Chia-Heng Li A Hsu C-Y, et al ."Small cell carcinomas in
gastrointestinal tract: immunohistochemical and clinicopathological
features". J Clin Pathol 2010;63:620-625
11.Ferolla P, Faggiano A, Mansueto G, et al. "The biological characterization
of neuroendocrine tumors: The role of neuroendocrine markers". J
endocrinol Invest 2008;31 (3): 277–286.
12.Grant CS. "Insulinoma". Best Pract Res Clin Gastroenterol 2005;19 (5):
783–798.
13.Griniatsos J, Michail O. "Appendiceal neuroendocrine tumors: Recent
insights and clinical implications". World J Gastrointest Oncol 2010;2 (4):
192-196.
14.Hagn C, Schmid KW,  Fischer-Colbrie R, et al. "ChromograninA, B and C
in human adrenal medulla and endocrine tissues". Lab Invest 1986; 55(4):
405-411.
15.Hauso O, Gustafsson BI, Kidd M, et al. "Neuroendocrine Tumor
Epidemiology". Cancer 2008;113(10): 2655-2664.
16.Hegde V, Mohandas KM, Ramadwar M, et al. "Gastric carcinoids – a
changing trend". Indian J Gastroenterol. 2003;22: 209–211.
17.Hodgson N, Koniaris LG, Livingstone AS, et al. "Gastric carcinoids: a
temporal increase with proton pump introduction". Surg Endosc 2005:19:
1610–1612.
18. Ito T, Tanaka M,  Sasano H,   et al.  "Preliminary   results  of   a   Japanese
nationwide survey  of  neuroendocrine gastrointestinal  tumors". J
Gastroenterol 2007;42: 497–500.
19. Jensen  RT, Berna M J, Bingham DB, et al. "Inherited pancreatic endocrine
tumor syndromes: Advances in molecular pathogenesis, diagnosis,
management, and controversies". Cancer 2008;113 (7): 1807–1843.
20.Kasprzak A, Zabel M, Biczysko W. "Selected Markers (Chromogranin A,
Neuron-Specific Enolase,Synaptophysin, Protein Gene Product 9.5) in
Diagnosis  and  Prognosis  of  Neuroendocrine Pulmonary  Tumours". Pol J
Pathol 2007;58(1):23–33.
21.Klimstra DS, Modlin IR, Coppola D, et al. "The Pathologic Classification
of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and
Staging Systems". Pancreas 2010;39(6): 707-712
22.Kloppel G, Perren A, Heitz PU. "The gastroenteropancreatic
neuroendocrine cell system and its  tumors: the WHO  classification".  Ann
N Y Acad Sci 2004; 1014: 13–27.
23.Konishi T, Watanabe T, Nagawa H, et al. "Treatment of colorectal
carcinoids:  A   new  paradigm".  World  J  Gastrointest  Surg  2010;2 (5):
153-156.
24.La Rosa S, Inzani F, Vanoli A, et al. "Histologic characterization and
improved prognostic evaluation of 209 gastric neuroendocrine neoplasms".
Hum Pathol 2011;42: 1373–1384.
25.La Rosa S, Marando A Sessa F, et al. "Mixed Adenoneuroendocrine
Carcinomas (MANECs) of the Gastrointestinal Tract: An Update".  Cancers
2012;4(1): 11-30
26.Langley K. "The Neuroendocrine Concept Today".  Annals of the New
York Academy of Sciences 1994;733: 1–17.
27.Lewin k. "Carcinoid tumors and the mixed (composite) glandular-endocrine
cell carcinomas". Am  J Surg  Pathol 1987;11(1):71-86.
28.Lin TY, Chao YC, Cheng MF. Primary Neuroendocrine Carcinoma of the
Esophagus J Med Sci 2007;27(2): 077-080
29.Liu Y, Sturgis CD, Grzybicki DM, et al. "Microtubule-associated protein-
2: a new sensitive and specific marker for pulmonary carcinoid tumor and
small cell carcinoma". Mod Pathol 2001;14 (9): 880–885.
30.Maggard MA, O'Connell JB, Ko CY. "Updated population-based review of
carcinoid tumors". Ann Surg 2004;240: 117-122.
31.Maroun J, Kocha W, Kvols L, et al. "Guidelines for the diagnosis and
management of carcinoid tumours. Part 1: the gastrointestinal tract. A
statement from a Canadian National Carcinoid Expert Group". Current
Oncology 2006;13(2): 67–76.
32.Massironi S,  Sciola V, Peracchi M, et al. "Neuroendocrine tumors of the
gastro-entero-pancreatic system". World J  Gastroenterol 2008;14 (35):
5377-5384.
33.Matsui K, Kitagawa M, Miwa A, et al. "Small cell carcinoma of the
stomach: a clinicopathologic study of 17 cases". Am J Gastroenterol
1991;86: 1167–1175.
34.Metz DC, Jensen RT. (2008). "Gastrointestinal Neuroendocrine Tumors:
Pancreatic Endocrine Tumors". Gastroenterology 2008;135 (5): 1469–1492.
35.Modlin IM, Lye KD, Kidd M. "A 50-year analysis of 562 gastric
carcinoids: small tumor or larger problem?". Am J Gastroenterol 2004;99:
23–32.
36.Modlin IM, Oberg K, Chung DC, et al. "Gastroenteropancreatic
neuroendocrine tumours". The Lancet Oncol 2008;9 (1): 61–72.
37.Modlin IM, Shapiro M D, Kidd M. "Siegfried oberndorfer: Origins and
perspectives of carcinoid tumors". Human Pathology 2004;35 (12): 1440–
1451.
38.Ni SJ, Sheng WQ, Du X. "Pathologic research update of colorectal
neuroendocrine tumors". World J Gastroenterol 2010;16(14): 1713–1719.
39.Niederle M B, Hackl M, Kaserer K, et al. "Gastroenteropancreatic
neuroendocrine tumours: the current incidence and staging based on the
WHO and European Neuroendocrine Tumour Society classification: an
analysis based on prospectively collected parameters".  Endocrine-Related
Cancer 2010;17: 909–918
40.Niederle M B, Niederle B. "Diagnosis and Treatment of
Gastroenteropancreatic Neuroendocrine Tumors: Current Data on a
Prospectively Collected, Retrospectively Analyzed Clinical Multicenter
Investigation". The Oncologist 2011 ;16(5): 602–613.
41.Öberg K, Castellano D. "Current knowledge on diagnosis and staging of
neuroendocrine tumors". Cancer Metastasis Reviews 2011,30(1): 3–7.
42.Öberg K. "Carcinoid Tumors: Current Concepts in Diagnosis and
Treatment". The oncologist 1998;3 (5): 339–345.
43.Oberg K. "Neuroendocrine tumors of the gastrointestinal tract: recent
advances in molecular genetics, diagnosis, and treatment". Curr Opin Oncol
Jul 2005;17 (4): 386–91.
44.Okita NT, Kato K, Takahari D, et al. "Neuroendocrine tumors of the
stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric
poorly-differentiated neuroendocrine carcinoma". Gastric Cancer 2011;14:
161–165.
45.Radhakrishnan S, Subramoniam S. "Colerectal carcinoids in South India".
Trop Geogr med 1979;31: 63-67.
46.Ramage JK, Davies AH, Ardill J, et al. "Guidelines for the management of
gastroenteropancreatic neuroendocrine (including carcinoid) tumours". Gut
2005;54 (suppl IV): iv1-iv16.
47.Reubi JC, Rivier J, Perrin M, et al. "Specific high affinity binding sites for
somatostatin-28 on pancreatic beta-cells: differences with brain
somatostatin receptors". Endocrinology 1982;110(3): 1049-1051.
48.Rindi G, Kloppel G, Alhman H, et al. "TNM staging of foregut
(neuro)endocrine tumors: a consensus proposal including a grading
system". Virchows Arch 2006;449: 395-401.
49.Rindi G, Kloppel G, Couvelard A, et al. "TNM staging of midgut and
hindgut (neuro)endocrine tumors: a consensus proposal including a grading
system". Virchows Arch 2007;451: 757-762
50.Rosa P, Hille A, Lee RW, et al. "Secretogranins I and 11, two tyrosine-
sulfated secretory proteins common to a variety of cells secreting peptides
by the regulated pathway". J Cell Biol 1985; 101(5): 1999-2011.
51.Rothenstein J, Cleary SP, Pond GR, et al. "Neuroendocrine tumors of the
gastrointestinal tract: a decade of experience at the Princess Margaret
Hospital". Am J Clin Oncol 2008;31(1): 64-70.
52.Rufini V,  Calcagni ML, Baum RP. "Imaging of neuroendocrine tumors".
Semin Nucl Med 2006;36 (3): 228–247.
53. Sippel RS, Chen H. "Carcinoid tumors". Surg Oncol Clin N Am 2006;15:
463-478.
54. Soga J, Yakuwa Y, Osaka M. "Carcinoid syndrome: a statistical evaluation
of  748  reported cases". J Exp Clin Cancer Res. 1999;18: 133–141.
55.Tan EH, Tan CH. "Imaging of gastroenteropancreatic neuroendocrine
tumors". World J Clin Oncol 2011;2 (1): 28-43.
56.Uchiyama C, Tamura S, Nakatsuka S, et al. "Immunohistochemical
consistency between primary tumors and lymph node metastases of gastric
neuroendocrine carcinoma. World J Surg Oncol. 2012;10:115.
57.Van Eeden S, Offerhaus G J, Hart AA, et al. "Goblet cell carcinoid of  the
appendix:  A specific type of carcinoma". Histopathology 2007;51 (6): 763–
773.
58.Warner,  Richardn RP. "Enteroendocrine Tumors Other Than Carcinoid: A
Review of Clinically Significant Advances". Gastroenterology 2005;128
(6): 1668–1684.
59.Warrell DA, Cox TM, Firth JD. Oxford Textbook of Medicine (4th ed.)
2003. Oxford University Press.
60.Warren WH, Welker M, Gattuso P. "Well-Differentiated Neuroendocrine
Carcinomas: The Spectrum of Histologic Subtypes and Various Clinical
Behaviors". Seminars in Thoracic and cardiovascular surgery 2006;18(3):
199-205.
Fig 1: Gastrectomy specimen showing  proliferative growth
measuring 5x4 cm in  NET G1
Fig 2:Subtotal  gastrectomy  specimen with ulcerative  growth
measuring 8x7cm in NET G3
Fig3: Hemicolectomy specimen showing ulceroproliferative growth
measuring 6x5 cm   in MANEC
Fig 4: Appendicectomy  specimen measuring  5cm in length. C/S tip
shows a small circumscribed tan yellow mass measuring 0.5cm in
NET G1
Fig 5: NET G1 arranged in nests and sheets. H&E10x view
Fig 6:Cells with scant eosinophilic cytoplasm and regular nuclei,
salt and pepper chromatin with less than two mitoses per HPFin
NETG1. H&E, 40x view
Fig 7:  Neoplastic cells arranged in cords, nests, trabecular pattern
in  NET G2.10x view., H&E
Fig 8: NET G2 showing ulcerated mucosa with neoplastic cells in
sub mucosa 10x view, H&E
Fig 9: NET G2 invading  the muscularis propria 10x view H&E
Fig 10 :  NETG2  involving Muscularis propria. H&E, 10x view
Fig 11: Cells  with scant eosinophilic cytoplasm, uniform nucleus,
finely stippled chromatin with mitoses 2-20 per HPF in NET G2.
45x view H&E
Fig 12: Cells in submucosa showing  round cells with clear
cytoplasm, round nuclei with clumped chromatin,>20 mitoses/10
HPF in NET G3.10x view. H&E
Fig 13: Round cells with clear cytoplasm, round nuclei with
clumped chromatin,>20 mitoses/10HPF in NET G3.45x view H&E
Fig 14 :  NSE positivity in NET G3.10x view.
Fig 15 :40x view showing neuron specificc enolase positivity
Fig 16: Scanner view showing synaptophysin positivity in well
differentiated neuroendocrine tumor
Fig 17:10x view showing synaptophysin positivity in a  well
differentiated neuroendocrine tumor
Fig 18:45x view showing synaptophysin positivity
Fig 19:10x view showing chromogranin positivity
Fig 20:40x view showing chromogranin positivity
CHART 1
CHART 2
CHART 3
CHART 4
CHART 5
CHART 6
CHART 7
CHART 8
s.no Biopsy no Age Sex LOA, LOW vomit abd pain diarrho jaundice Bleeding PR secondaries Carcinoid syn
Sample
received Site Diag NSE SYN CGA
1 52/08 71 M 1 0 1 0 0 0 0 0 MGWST smallintestine NEC 1 0 02 169/08 61 M 0 1 1 0 0 0 0 0 MGWST Stomach NEC 1 1 1
3 752/08 50 F 1 0 1 0 0 0 0 1 MGWST smallintestine NET G1 1 1 14 2641/08 40 F 0 0 1 1 0 0 0 0 MGWST smallintestine NET G1 1 1 15 3123/08 61 M 0 0 1 0 0 0 0 0 Gastrectomy Stomach NET G2 1 0 1
6 3428/08 32 F 0 0 0 0 1 0 0 0 Whipple's proc smallintestine MANEC 1 0 17 842/09 58 M 0 0 0 0 0 0 0 0 MGWST smallintestine NET G1 1 1 18 R940/09 64 M 0 0 0 0 0 1 0 0 MGWST Colon MANEC 1 1 1
9 1164/09 60 F 1 0 1 0 0 0 0 0 Subtotalcolectomy Colon NEC 1 1 010 1277/09 62 F 1 0 0 0 0 0 0 0 MGWST Colon NEC 0 0 1
11 2821/09 37 M 0 0 1 0 0 1 0 0 MGWST Rectum NET G1 1 1 0
12 2180/09 40 F 0 0 1 0 0 0 0 0 MGWST Appendix NET G1 1 1 1
13 R1169/09 50 F 0 0 0 0 0 0 0 0 MGWST Stomach NET G1 1 1 1
14 458/10 35 M 0 0 1 0 1 0 0 0 MGWST smallintestine NET G1 1 1 115 R640/10 40 M 1 0 0 0 0 0 0 0 MGWST smallintestine NET G1 1 1 116 685/10 25 M 1 0 1 1 0 0 1 0 MGWST Rectum MANEC 1 1 0
17 924/10 40 F 0 1 1 0 0 0 1 0 MGWST Stomach NET G2 1 1 1
18 1021/10 43 F 0 0 0 0 0 0 0 0 MGWST Stomach NET G2 1 1 0
19 R1045/10 70 M 1 0 1 0 0 0 0 0 MGWST smallintestine NET G2 1 1 120 R1084/10 50 M 0 0 0 0 0 1 0 0 MGWST Rectum NET G2 1 1 1
21 1310/10 60 M 0 1 1 0 0 0 0 0 MGWST Stomach MANEC 0 1 0
22 1541/10 30 M 0 0 1 0 0 0 0 0 MGWST Stomach NET G1 1 1 1
23 1430/10 45 M 1 0 0 0 0 0 0 0 MGWST Stomach NET G2 1 1 1
24 1634/10 45 M 1 0 1 0 0 0 0 0 MGWST Stomach NET G2 1 1 1
25 1890/10 51 F 0 0 0 0 0 0 0 0 MGWST oesopagus NET G1 1 1 1
26 2035/10 60 F 1 0 0 0 0 0 0 0 MGWST Stomach MANEC 1 0 0
27 107/11 60 M 0 0 1 0 0 0 0 1 MGWST Stomach NET G1 1 1 1
28 404/11 62 F 0 0 1 0 1 0 0 0 MGWST smallintestine NET G1 1 1 129 446/11 70 M 1 0 1 0 1 0 0 0 MGWST Stomach NET G1 1 1 1
30 R798/11 55 M 0 0 0 0 0 0 0 0 MGWST smallintestine NET G1 1 1 10= absent 1=present 0=neg 1=pos
s.no Biopsy no Age Sex LOA, LOW vomit abd pain diarrho jaundice Bleeding PR secondaries Carcinoid syn
Sample
received Site Diag NSE SYN CGA
31 R1076/11 50 F 0 0 1 0 1 0 0 0 MGWST smallintestine NET G1 1 1 1
32 R1202/11 54 F 1 0 0 0 0 0 0 0 totalgastrectomy Stomach NET G1 1 1 1
33 1448/11 55 F 0 0 0 0 0 0 0 0 MGWST smallintestine MANEC 1 1 1
34 1733/11 59 M 0 1 1 0 0 0 0 0 MGWST Stomach MANEC 1 1 1
35 1775/11 49 F 0 1 1 0 0 0 0 0 MGWST Stomach MANEC 1 1 1
36 2410/11 57 M 1 0 0 0 0 0 0 0 MGWST Stomach MANEC 1 1 1
37 2441/11 55 F 0 0 0 0 0 0 0 0 MGWST smallintestine NET G1 1 1 1
38 563/12 47 M 1 0 0 0 0 0 0 0 sub gastrectomy Stomach MANEC 1 1 1
39 1339/12 45 M 0 1 1 0 0 0 0 0 MGWST Stomach NET G1 1 1 1
40 1359/12 54 M 1 0 0 0 0 0 0 0 MGWST Stomach NET G1 1 1 1
41 650/08 48 M 0 0 0 0 0 0 1 0 Hemicolectomy Colon MANEC ND ND ND
42 R1104/08 70 F 1 0 0 0 0 0 0 0 MGWST smallintestine MANEC ND ND ND
43 2437/08 27 F 0 0 0 0 0 0 0 0 Ileal resection smallintestine NET G2 ND ND ND
44 2842/08 40 M 1 0 0 0 0 0 0 0 MGWST smallintestine NET G1 ND ND ND
45 3092/08 50 M 0 0 0 0 0 1 0 0 APR Rectum NET G1 ND ND ND
46 460/09 43 M 1 0 1 0 0 0 0 0 MGWST Stomach NET G1 ND ND ND
47 R262/09 40 M 1 0 1 0 0 0 0 0 MGWST smallintestine MANEC ND ND ND
48 1007/09 37 M 0 1 1 0 0 0 0 0 MGWST Stomach NET G2 ND ND ND
49 2139/09 65 M 0 1 1 0 0 0 0 0 MGWST Stomach MANEC ND ND ND
50 1690/10 52 M 0 0 1 0 0 0 0 0 MGWST Colon MANEC ND ND ND
51 146/12 38 F 1 0 0 0 0 0 0 0 MGWST smallintestine MANEC ND ND ND
52 402/12 49 M 0 1 1 0 0 0 0 0 MGWST Stomach MANEC ND ND ND
53 689/11 56 F 1 0 0 0 0 0 0 0 MGWST Stomach MANEC ND ND ND
0= absent 1=present 0=neg 1=pos ND=notdone
ANNEXURE
Tumour, Node, Metastasis (TNM) staging system for Gastric
Neuroendocrine Tumors:
(T) Primary tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ/dysplasia (tumor size < 0.5 mm),
confined to mucosa
T1 Tumor invades lamina propria, or   submucosa and ≤ 1cm
insize
T2 Tumor invades muscularis propria or > 1 cm in size
T3 Tumor penetrates subserosa
T4 Tumor invades visceral peritoneum (serosal) or other
organs or adjacent structures
For any T, (m) should be added for multiple tumors
Regional lymphnodes (N)
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
STAGE GROUPING
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage IIA T2 N0 M0
Stage IIB T3 N0 M0
Stage IIIA T4 N0 M0
Stage IIIB Any T N1 M0
Stage IV Any T Any N M1
Tumour, Node, Metastasis (TNM) staging system for Neuroendocrine
Tumors duodenum/ampulla/jejunum/ileum:
(T) Primary tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor invades lamina propria,or   submucosa and ≤ 1cm in
size(Small intestinal tumors);tumor ≤ 1 cm (Ampullary
tumors)
T2 Tumor invades muscularis propria  or > 1 cm in size(Small
intestinal tumors) );tumor > 1 cm (Ampullary    tumors)
T3 Tumor  invades through the muscularis propria  into the
` subserosal tissue without penetration of the overlying
serosa(Jejunal or Ileal tumors) or invades Pancreas or
Retroperitoneum(Ampullary or Duodenal  tumors) or into
non retroperitonealized tissues
T4 Tumor invades visceral peritoneum (serosa) or invades
other organs
For any T, (m) should be added for multiple tumors
Regional lymph nodes (N)
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
STAGE GROUPING
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage IIA T2 N0 M0
Stage IIB T3 N0 M0
Stage IIIA T4 N0 M0
Stage IIIB Any T N1 M0
Stage IV Any T Any N M1
[TNM classification of malignant tumours (7th edition). International Union Against
Cancers http://www.uiccorg/tnm 2010]
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ABSTRACT
Neuroendocrine tumors are relatively rare neoplasms that arise in
various organs and share many common pathological features. In the
year 2010 WHO graded Neuroendocrine tumors based on mitotic rate
and Ki-67 index into NET G1, NET G2, NET G3 and Mixed
adenoneuroendocrine carcinomas. The objectives of this study were to
evaluate clinicopathological, histomorphological and
immunohistochemical features of neuroendocrine tumors of the
gastrointestinal tract. In this study, a total of 53 specimens received
between 2008 and 2012 diagnosed as having neuroendocrine tumors of
GIT were analysed for histopathological and immunohistochemical
expression. Results: In our study neuroendocrine tumors of git were
more common in males. The most common anatomical location was
stomach. The median age at diagnosis was fifty. Most of the tumors
were NET G1.We found MANEC to have a higher incidence. The
positivity rates for NSE, Synaptophysin and chromogranin A was
97.5%, 87.5% and 82.5% respectively. Conclusion: The incidence of
neuroendocrine tumors is on the rise. Immunohistochemical
confirmation of histopathological diagnosis is important to distinguish
NETs from other neoplasms and to give a definitive diagnosis.
Keywords:Neuroendocrine tumors,Carcinoids,immunohistochemistry


